Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | hypothetical protein, conserved | 0.0026 | 0.012 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0025 | 0.0096 | 0.0252 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0087 | 0.1053 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0026 | 0.012 | 0.012 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0026 | 0.012 | 0.5 |
Mycobacterium ulcerans | fatty-acid-CoA ligase | 0.0025 | 0.0096 | 0.0096 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.0026 | 0.012 | 0.5 |
Mycobacterium ulcerans | long-chain-fatty-acid-CoA ligase | 0.0025 | 0.0096 | 0.0096 |
Loa Loa (eye worm) | glutaminase 2 | 0.0265 | 0.3795 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0025 | 0.0096 | 0.0252 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0087 | 0.1053 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.0025 | 0.0096 | 0.0096 |
Plasmodium vivax | beta-ketoacyl-acyl carrier protein synthase III precursor, putative | 0.0667 | 1 | 1 |
Echinococcus granulosus | tumor protein p63 | 0.035 | 0.5108 | 0.5 |
Mycobacterium tuberculosis | 3-oxoacyl-[acyl-carrier-protein] synthase III FabH (beta-ketoacyl-ACP synthase III) (KAS III) | 0.0667 | 1 | 1 |
Mycobacterium ulcerans | acyl-CoA synthetase | 0.0025 | 0.0096 | 0.0096 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0087 | 0.1053 | 1 |
Mycobacterium ulcerans | beta-ketoacyl synthase-like protein | 0.0667 | 1 | 1 |
Mycobacterium ulcerans | acyl-CoA synthetase | 0.0025 | 0.0096 | 0.0096 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0087 | 0.1053 | 1 |
Mycobacterium tuberculosis | Probable chain -fatty-acid-CoA ligase FadD13 (fatty-acyl-CoA synthetase) | 0.0025 | 0.0096 | 0.0096 |
Brugia malayi | glutaminase DH11.1 | 0.0265 | 0.3795 | 1 |
Mycobacterium ulcerans | long-chain-fatty-acid--CoA ligase | 0.0025 | 0.0096 | 0.0096 |
Loa Loa (eye worm) | hypothetical protein | 0.0051 | 0.0506 | 0.1334 |
Mycobacterium ulcerans | long-chain fatty-acid CoA ligase | 0.0025 | 0.0096 | 0.0096 |
Mycobacterium tuberculosis | Probable fatty-acid-CoA ligase FadD2 (fatty-acid-CoA synthetase) (fatty-acid-CoA synthase) | 0.0025 | 0.0096 | 0.0096 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.0667 | 1 | 1 |
Mycobacterium leprae | PROBABLE FATTY-ACID-CoA LIGASE FADD7 (FATTY-ACID-CoA SYNTHETASE) (FATTY-ACID-CoA SYNTHASE) | 0.0025 | 0.0096 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | 3-oxoacyl-ACP synthase | 0.0667 | 1 | 0.5 |
Trichomonas vaginalis | glutaminase, putative | 0.0265 | 0.3795 | 0.5 |
Plasmodium falciparum | beta-ketoacyl-ACP synthase III | 0.0667 | 1 | 1 |
Loa Loa (eye worm) | glutaminase | 0.0265 | 0.3795 | 1 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0026 | 0.012 | 0.5 |
Schistosoma mansoni | glutaminase | 0.0265 | 0.3795 | 1 |
Brugia malayi | hypothetical protein | 0.0026 | 0.012 | 0.0065 |
Loa Loa (eye worm) | hypothetical protein | 0.0025 | 0.0096 | 0.0252 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.0667 | 1 | 1 |
Onchocerca volvulus | 0.0051 | 0.0506 | 1 | |
Mycobacterium leprae | PROBABLE FATTY-ACID-CoA LIGASE FADD2 (FATTY-ACID-CoA SYNTHETASE) (FATTY-ACID-CoA SYNTHASE) | 0.0025 | 0.0096 | 0.5 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0026 | 0.012 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0026 | 0.012 | 0.0315 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0026 | 0.012 | 0.012 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0087 | 0.1053 | 1 |
Mycobacterium ulcerans | glutaminase | 0.0265 | 0.3795 | 0.3795 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0026 | 0.012 | 0.012 |
Echinococcus multilocularis | tumor protein p63 | 0.035 | 0.5108 | 0.5 |
Mycobacterium ulcerans | acyl-CoA synthetase | 0.0025 | 0.0096 | 0.0096 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.